Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Organovo Holdings
(NQ:
ONVO
)
0.6188
+0.0478 (+8.37%)
Streaming Delayed Price
Updated: 3:53 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Organovo Holdings
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
July 16, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
May 21, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
May 14, 2024
Renowned gastrointestinal diseases conference to held in Washington, D.C. May 18-21, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
May 08, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
April 15, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
January 25, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
January 09, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
December 06, 2023
From
Organovo, Inc.
Via
GlobeNewswire
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
November 13, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Organovo Highlights FXR314 Combination Therapy Potential and Plan
November 08, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Organovo to Participate in the H.C. Wainwright Global Investment Conference
September 08, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
August 23, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Organovo Announces FXR Program
March 21, 2023
Lead Molecule Poised for Phase 2 in IBD
From
Organovo, Inc.
Via
GlobeNewswire
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates
November 15, 2022
From
Organovo, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.